Company Profile
DSM-Firmenich AG provides nutrition, health, and beauty solutions in Switzerland, the Netherlands, rest of Europe, the Middle East and Africa, North America, Latin America, China, and rest of Asia. The company operates through Perfumery & Beauty; Taste, Texture & Health; and Health, Nutrition & Care segments. The Perfumery & Beauty creates scents using natural, synthetic, and biotech ingredients. The Taste, Texture & Health segment provides food and beverages solutions, including flavors, natural extracts, and sugar reduction; and food enzymes, hydrocolloids, cultures, natural colorants, nutritional ingredients, and plant-based proteins. The Health, Nutrition & Care segment provides solutions for the early life nutrition, dietary supplement, pharmaceutical, medical nutrition, biomedical materials, and nutrition improvement markets. This segment also offers vitamins, nutritional lipids, minerals, carotenoids, botanical nutraceuticals, digestive enzymes, postbiotics, probiotics and prebiotics, and active pharmaceutical ingredients; biomedical solutions; and premix, market-ready, and personalized nutrition solutions, as well as expert services in regulatory affairs and nutrition. DSM-Firmenich AG was founded in 1902 and is based in Kaiseraugst, Switzerland.
Latest News
AstraZeneca Q2 Core Earnings, Revenue Rise
The9 Names George Lai as CEO
Far-right Australian politician loses appeal in racism case
Itron (ITRI) To Report Earnings Tomorrow: Here Is What To Expect
Modern agriculture emerges as high-tech industry: Chairman of Wens Foodstuff Group
| Sector | Basic Materials |
| Industry | Specialty Chemicals |
| Website | https://www.dsm-firmenich.com |
| Audit Risk | 1 |
| Board Risk | 2 |
| Overall Risk | 1 |
| Market Cap | 20.28B |
| Trailing P/E | 67.9 |
| Forward P/E | 20.74 |
| Dividend Rate | 2.5 |
| Dividend Yield | 3.07% |
| Trailing Annual Div. Rate | 2.5 |
| Trailing Annual Div. Yield | 3.07% |
| Trailing EPS | 1.21 |
| Forward EPS | 3.96 |
| Book Value | 72.53 |
| Price-to-Book | 1.13 |
| Enterprise-to-Revenue | 2.66 |
| Enterprise-to-EBITDA | 16.71 |
| Ex-Dividend Date | 05/11/2026 |
| Earnings Date | |
| Earnings Call Date | 07/30/2026 |
| Earnings Average | 0.89 |
| Earnings Low | 0.89 |
| Earnings High | 0.89 |
| Revenue Average | 2.33B |
| Revenue Low | 2.32B |
| Revenue High | 2.35B |